Related Experiment Videos

Correlation Between Apolipoprotein B and Severity of Coronary Artery Stenosis in Individuals Aged 45 and Above: A

Dingchao Lv1,2,3, Mao Ye4,5, He Huang4,5

  • 1The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China, sxmu.edu.cn.

Cardiovascular Therapeutics
|August 6, 2026
PubMed

Insights

Elevated Apolipoprotein B (ApoB) levels are significantly associated with more severe coronary artery stenosis in individuals over 45. This finding highlights ApoB as a potential biomarker for assessing cardiovascular risk.

Area of Science:

  • Cardiology
  • Biomarkers
  • Medical Research

Background:

  • Apolipoprotein B (ApoB) is a recognized biomarker for cardiovascular risk.
  • The relationship between ApoB levels and the severity of coronary artery stenosis (Gensini score) in individuals aged 45 and above requires further investigation.

Purpose of the Study:

  • To investigate the correlation between Apolipoprotein B (ApoB) levels and the severity of coronary artery stenosis, as measured by the Gensini score.
  • To evaluate ApoB as a potential biomarker for assessing cardiovascular risk in patients aged 45 and older.

Main Methods:

  • A retrospective cross-sectional analysis of 818 patients undergoing coronary angiography.
  • Measurement of lipid parameters, including ApoB, from fasting blood samples.
  • Assessment of coronary artery stenosis severity using the Gensini score and multivariate regression analysis to determine associations.

Main Results:

  • Patients with moderate-to-severe stenosis (Gensini score ≥ 36) exhibited significantly higher ApoB levels compared to those with mild stenosis (Gensini score < 36).
  • Multivariate regression confirmed ApoB as an independent predictor of moderate-to-severe coronary stenosis (β = 46.1, p < 0.001).
  • A consistent positive correlation was observed between higher ApoB levels and increased Gensini scores across all clinical subgroups.

Conclusions:

  • Apolipoprotein B (ApoB) levels show a significant positive correlation with the severity of coronary artery stenosis in individuals aged 45 and above.
  • These findings suggest ApoB holds potential clinical value for evaluating coronary artery disease severity.
Abstract

Keywords:
Apolipoprotein BGensini scorecoronary artery disease

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...